Search

Your search keyword '"Boucher, Ken"' showing total 39 results
Start Over Author "Boucher, Ken"
39 results on '"Boucher, Ken"'

3. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy

Author

Tward, Jonathan D., O’Neil, Brock, Boucher, Ken, Kokeny, Kristine, Lowrance, William T., Lloyd, Shane, Cannon, Donald, Stephenson, Robert A., Agarwal, Neeraj, Farr, Tyler, Petragallo, Rachel, Sherar, Nia Z., Kunz, Isaac, Hofer, Andrew, Courdy, Samir, Shrieve, Dennis C., and Dechet, Christopher

Published
2020
Full Text
View/download PDF

9. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes

Author

Wagner, Charlotte B., primary, Boucher, Ken, additional, Nedved, Adrienne, additional, Micallef, Ivana N, additional, Desai, Sanjal, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A., additional, Ermann, Daniel A., additional, Fitzgerald, Lindsey A., additional, Hu, Boyu, additional, Stephens, Deborah M., additional, and Shah, Harsh, additional

Published
2023
Full Text
View/download PDF

11. O019/#977 Short course adjuvant vaginal cuff brachytherapy in early endometrial cancer: adverse events and early patient reported outcomes

Author

Burt, Lindsay, primary, Huang, Jessica, additional, Boucher, Ken, additional, Suneja, Gita, additional, Decesaris, Cristina, additional, Grant, Jonathan, additional, Harkenrider, Matthew, additional, Jhingran, Anuja, additional, Kidd, Elizabeth, additional, Lin, Lilie, additional, Small, William, additional, and Gaffney, David, additional

Published
2022
Full Text
View/download PDF

13. Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Author

Wagner, Charlotte B, primary, Ermann, Daniel A., additional, Boucher, Ken, additional, Nedved, Adrienne N., additional, Micallef, Ivana N., additional, Desai, Sanjal H, additional, Hatic, Haris, additional, Goyal, Gaurav, additional, Zacholski, Erin, additional, Fegley, Amanda, additional, Sigmund, Audrey M., additional, Bond, David A., additional, Samuels, Courtney, additional, Kamdar, Manali K., additional, Ba Aqeel, Sheeba, additional, Torka, Pallawi, additional, MacDougall, Kira, additional, Borogovac, Azra, additional, Rajeeve, Sridevi, additional, Sundaram, Suchitra, additional, Fedak, Kalub, additional, Modi, Dipenkumar, additional, Travers, Elizabeth, additional, Ayyappan, Sabarish, additional, Chilakamarri, Nitin, additional, Brem, Elizabeth A, additional, Stephens, Deborah M., additional, Hu, Boyu, additional, Fitzgerald, Lindsey A., additional, and Shah, Harsh, additional

Published
2022
Full Text
View/download PDF

14. PO29 Presentation Time: 7:40 AM

Author

Kunz, Jeremy, primary, Huang, Y. Jessica, additional, Casper, Anthony C., additional, Suneja, Gita, additional, Burt, Lindsay M., additional, Jhingran, Anuja, additional, Joyner, Melissa M., additional, Harkenrider, Matt, additional, Small, William, additional, Grant, Johnathan D., additional, Kidd, Elizabeth A., additional, Boucher, Ken, additional, and Gaffney, David K., additional

Published
2022
Full Text
View/download PDF

15. Comparison of Diagnostic Sensitivity and Procedure-Related Pain of Concurrent Ultrasound-guided Fine-needle Aspiration and Core-needle Biopsy of Axillary Lymph Nodes in Patients with Suspected or Known Breast Cancer.

Author

Winkler, Nicole, Buxton, Jace, Freer, Phoebe, Raps, Evan, Barraza, Gonzalo, Boucher, Ken, Riegert, Joanna, and Factor, Rachel

Subjects
BREAST tumor diagnosis, ULTRASONIC imaging, PAIN, LYMPH nodes, SURGICAL complications, MANN Whitney U Test, DESCRIPTIVE statistics, RESEARCH funding, DATA analysis, NEEDLE biopsy, AXILLARY lymph node dissection, LONGITUDINAL method
Abstract

Objective: Conflicting data exist on the diagnostic sensitivity of core-needle biopsy (CNB) compared to fine-needle aspiration (FNA) in the evaluation of axillary lymph node metastasis from breast cancer. Our purpose was to evaluate the sensitivity of CNB and FNA using subsequent axillary surgery as the gold standard and to compare the patients' subjective pain levels for each biopsy method. Methods: This IRB-approved prospective study enrolled 140 patients from February 2014 to May 2019 with known or suspected breast cancer. Patients underwent both US-guided FNA and 14-gauge CNB of the same node with clip placement and rated their pain level using a verbal numerical rating scale of 0 to 10. The diagnostic sensitivities were determined by pathology of the surgically excised lymph node using the McNemar test of correlated proportions. Changes in pain scores for CNB and FNA were determined using the Wilcoxon rank sum test. Results: A total of 94 patients had confirmatory excision of the biopsied node with nodal metastasis detected in 71.3% (67/94). The sensitivity of CNB for detection of nodal metastasis was 95.5% (64/67), while the sensitivity of FNA was 67.2% (45/67) (P < 0.05). Overall pain score ratings for CNB increased by 0.6 from baseline on an 11-point numerical rating scale, while overall pain score rating for FNA decreased by 0.2 from baseline (P < 0.05). Conclusion: Our study demonstrates that 14-gauge CNB has superior sensitivity for detection of axillary nodal metastases and mildly increased pain compared with 25-gauge FNA in patients with breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Familial mortality in the Utah Population Database: characterizing a human aging phenotype

Author

O'Brien, Elizabeth, Kerber, Richard, Smith, Ken, Mineau, Geraldine, Boucher, Ken, and Reed, Diana Lane

Subjects
Longevity -- Evaluation, Mortality -- United States, Mortality -- Causes of, Family assessment -- Health aspects, Health, Seniors
Abstract

We examine the effects of familial longevity and familial mortality on mortality rates for 10 leading causes of death in a Utah Population Database (UPDB) cohort. Familial excess longevity (FEL) and familial standardized mortality ratios (FSMR) were estimated for 666,921 individuals born from 1830 through 1963, who survived to at least age 40. Cox regression analysis shows that familial death and familial longevity have independent effects on cause-specific mortality rates for 10 leading causes of death. A family history of disease increases one's risk of dying from the same cause, whereas a family history of longevity is protective, except in the case of cancer. Families with greater longevity do not die of causes distinct from other members of the cohort, but they die from the same causes at reduced rates. Individuals from longer lived families have lower mortality from most age-related diseases including heart disease, stroke, and diabetes, but not cancer.

Published
2007

20. Calibration of Multiple In Silico Tools for Predicting Pathogenicity of Mismatch Repair Gene Missense Substitutions

Author

Thompson, Bryony A., Greenblatt, Marc S., Vallee, Maxime P., Herkert, Johanna C., Tessereau, Chloe, Young, Erin L., Adzhubey, Ivan A., Li, Biao, Bell, Russell, Feng, Bingjian, Mooney, Sean D., Radivojac, Predrag, Sunyaev, Shamil R., Frebourg, Thierry, Hofstra, Robert M.W., Sijmons, Rolf H., Boucher, Ken, Thomas, Alun, Goldgar, David E., Spurdle, Amanda B., and Tavtigian, Sean V.

Published
2013
Full Text
View/download PDF

21. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration

Author

Stephens, Deborah M., primary, Boucher, Ken, additional, Kander, Elizabeth, additional, Parikh, Sameer A., additional, Parry, Erin M., additional, Shadman, Mazyar, additional, Pagel, John M., additional, Cooperrider, Jennifer, additional, Rhodes, Joanna, additional, Mato, Anthony, additional, Winter, Allison, additional, Hill, Brian, additional, Gaballa, Sameh, additional, Danilov, Alexey, additional, Phillips, Tycel, additional, Brander, Danielle M., additional, Smith, Sonali M., additional, Davids, Matthew, additional, Rogers, Kerry, additional, Glenn, Martha J., additional, and Byrd, John C., additional

Published
2020
Full Text
View/download PDF

22. Abstract A06: Associations of prediagnostic metabolomic profiles with colorectal cancer risk—a collaborative reanalysis within the COnsortium of METabolomic Studies (COMETS)

Author

Ose, Jennifer, primary, Ulrich, Cornelia M., additional, Playdon, Mary, additional, Boucher, Ken, additional, Elisassen, A. Heather, additional, Shu, Xia-Ou, additional, Zheng, Wei, additional, Metspalu, Andres, additional, Esku, Tonu, additional, Lasky-Su, Jessica, additional, Moore, Steve, additional, and Gunter, Marc, additional

Published
2020
Full Text
View/download PDF

25. Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

Author

Stephens, Deborah M., primary, Boucher, Ken, additional, Kander, Elizabeth, additional, Parikh, Sameer A., additional, Parry, Erin, additional, Shadman, Mazyar, additional, Pagel, John M., additional, Cooperrider, Jennifer, additional, Rhodes, Joanna, additional, Mato, Anthony R., additional, Winter, Allison M., additional, Hill, Brian T., additional, Gaballa, Sameh, additional, Danilov, Alexey V, additional, Phillips, Tycel J., additional, Brander, Danielle M., additional, Smith, Sonali M., additional, Davids, Matthew S, additional, Rogers, Kerry A., additional, Glenn, Martha, additional, and Byrd, John C., additional

Published
2018
Full Text
View/download PDF

27. Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker

Author

Cohen, Adam L., primary, Neumayer, Leigh, additional, Boucher, Ken, additional, Factor, Rachel E., additional, Shrestha, Gajendra, additional, Wade, Mark, additional, Lamb, John G., additional, Arbogast, Kylee, additional, Piccolo, Stephen R., additional, Riegert, Joanna, additional, Schabel, Matthias, additional, Bild, Andrea H., additional, and Werner, Theresa L., additional

Published
2017
Full Text
View/download PDF

29. Resolving the Functional Significance of BRCA1 RING Domain Missense Substitutions

Author

Paquette, Andrew, primary, Tao, Kayoko, additional, Clark, Kathleen A, additional, Stark, Alex W, additional, Rosenthal, Judith, additional, Snow, Angela K, additional, Bell, Russell, additional, Thompson, Bryony A, additional, Unger, Joshua, additional, Milash, Brett A, additional, Pappas, Lisa, additional, Gertz, Jason, additional, Varley, Katherine E, additional, Thomas, Alun, additional, Boucher, Ken, additional, Foulkes, William D, additional, Goldgar, David E, additional, and Tavtigian, Sean V, additional

Published
2016
Full Text
View/download PDF

31. Characteristics of Missed or Interval Colorectal Cancer and Patient Survival: A Population-Based Study

Author

Samadder, N. Jewel, primary, Curtin, Karen, additional, Tuohy, Thérèse M.F., additional, Pappas, Lisa, additional, Boucher, Ken, additional, Provenzale, Dawn, additional, Rowe, Kerry G., additional, Mineau, Geraldine P., additional, Smith, Ken, additional, Pimentel, Richard, additional, Kirchhoff, Anne C., additional, and Burt, Randall W., additional

Published
2014
Full Text
View/download PDF

34. Calibration of Multiple In Silico Tools for Predicting Pathogenicity of Mismatch Repair Gene Missense Substitutions

Author

Thompson, Bryony A., primary, Greenblatt, Marc S., additional, Vallee, Maxime P., additional, Herkert, Johanna C., additional, Tessereau, Chloe, additional, Young, Erin L., additional, Adzhubey, Ivan A., additional, Li, Biao, additional, Bell, Russell, additional, Feng, Bingjian, additional, Mooney, Sean D., additional, Radivojac, Predrag, additional, Sunyaev, Shamil R., additional, Frebourg, Thierry, additional, Hofstra, Robert M.W., additional, Sijmons, Rolf H., additional, Boucher, Ken, additional, Thomas, Alun, additional, Goldgar, David E., additional, Spurdle, Amanda B., additional, and Tavtigian, Sean V., additional

Published
2012
Full Text
View/download PDF

38. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

Author

Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, and Shah H

Subjects
Humans, Brentuximab Vedotin, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Stem Cell Transplantation, Chronic Disease, Treatment Outcome, Hodgkin Disease drug therapy, Hodgkin Disease pathology, Immunoconjugates adverse effects
Abstract

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose due to toxicity. This retrospective, multicenter study investigated the effect of cumulative maintenance BV dose on 2-year PFS. Data were collected from patients who received at least one cycle of BV maintenance after ASCT with one of the following high-risk features: primary refractory disease (PRD), extra-nodal disease (END), or relapse <12 months (RL<12) from the end of frontline therapy. Cohort 1 had patients with >75% of the planned total cumulative dose, cohort 2 with 51-75% of dose, and cohort 3 with ≤50% of dose. The primary outcome was 2-year PFS. A total of 118 patients were included. Fifty percent had PRD, 29% had RL<12, and 39% had END. Forty-four percent of patients had prior exposure to BV and 65% were in complete remission before ASCT. Only 14% of patients received the full planned BV dose. Sixty-one percent of patients discontinued maintenance early and majority of those (72%) were due to toxicity. The 2-year PFS for the entire population was 80.7%. The 2-year PFS was 89.2% for cohort 1 (n=39), 86.2% for cohort 2 (n=33), and 77.9% for cohort 3 (n=46) (P=0.70). These data are reassuring for patients who require dose reductions or discontinuation to manage toxicity.

Published
2023
Full Text
View/download PDF

39. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.

Author

Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, and Byrd JC

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin therapeutic use, Dacarbazine therapeutic use, Disease-Free Survival, Doxorubicin therapeutic use, Humans, Retrospective Studies, Vinblastine therapeutic use, Hodgkin Disease diagnosis, Hodgkin Disease epidemiology, Hodgkin Disease therapy, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell epidemiology, Leukemia, Lymphocytic, Chronic, B-Cell therapy
Abstract

Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We conducted a multi-center retrospective study of patients with Hodgkin Transformation (HT) of CLL. Clinicobiologic characteristics, treatment type, and survival outcomes were analyzed and compared with historic case series. Ninety-four patients were identified. Median age at HT was 67 years (range, 38-85). Median time from CLL diagnosis to HT was 5.5 years (range, 0-20.2). Prior to HT, patients received a median of 2 therapies for CLL (range, 0-12). As initial therapy for HT, 61% (n=62) received ABVD-based regimens (adriamycin, bleomycin, vinblastine, and dacarbazine). Seven (7%) patients received hematopoietic cell transplantation (HCT) while in first complete remission (CR1). The median number of treatments for HT per patient was 1 (range, 0-5) with 59 (61%) patients only receiving one line of therapy. After HT, patients had a median follow-up of 1.6 years (range, 0-15.1). Two-year overall survival (OS) after HT diagnosis was 72% (95%CI 62-83%). The patients who received standard ABVD-based therapy had a median OS of 13.2 years. Although limited by small sample size, the patients who underwent HCT for HT in CR1 had a similar 2-year OS (n=7; 67%) compared to patients who did not undergo HCT for HT in CR1 (n=87; 72%; p=0.46). In this multi-center study, HT patients treated with ABVD-based regimens had prolonged survival supporting the use of these regimens as standard of care for these patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results